Buprenorphine extended-release injection (Brixadi ®) in the management of opioid use disorder: a profile of its use in the USA
AbstractBuprenorphine extended-release (ER) injection for subcutaneous use (Brixadi®; CAM2038; hereafter referred to as buprenorphine ER) is a useful addition to the treatment options for opioid use disorder (OUD). Brixadi® is formulated using FluidCrystal® injection depot technology, allowing for a low volume prefilled syringe and steady release of buprenorphine over one week or one month. In a pivotal phase 3 trial, weekly or monthly subcutaneous buprenorphine ER was non-inferior to daily sublingual buprenorphine/naloxone in terms of the proportion of opioid-negative urine samples and the responder rate. Based on th...
Source: Drugs and Therapy Perspectives - March 15, 2024 Category: Drugs & Pharmacology Source Type: research
Comparing attention, impulsivity, and executive functions between patients with opiate use disorder: Buprenorphine maintenance treatment versus active users, in comparison with healthy controls
CONCLUSION: The data from this study indicate that individuals with OUD exhibit neurocognitive damage, and those in remission from OUD who receive maintenance treatment do not show improvement in this domain. Neurocognitive damages should be considered in long-term treatment planning of patients with OUD.PMID:38419927 | PMC:PMC10898529 | DOI:10.4103/indianjpsychiatry.indianjpsychiatry_520_23 (Source: Indian Journal of Psychiatry)
Source: Indian Journal of Psychiatry - February 29, 2024 Category: Psychiatry Authors: Didem Be şikci Keleş Rabia Bilici Batuhan Ay ık Muhsin Koray K ılıç Wendy Kliewer Source Type: research
Treatment for Opioid Use Disorder in'Bridge' Clinics Offers Some Advantages, Study Finds
Hospitalized patients with opioid use disorder who were referred to an on-site clinic that provides wraparound services during the transition to outpatient care (a bridge clinic) reported fewer overdoses and more refills of medications like buprenorphine in the weeks following discharge, astudy inJAMA Network Open found. However, the use of the bridge clinic was not associated with a faster discharge compared with usual opioid use disorder (OUD) care, nor did it reduce hospital readmissions or health care costs.“Bridge clinics offer presumed care advantages, including timely provision of [medications] while a long-term c...
Source: Psychiatr News - February 28, 2024 Category: Psychiatry Tags: Bridge clinic buprenorphine length of stay medications for opioid use disorder MOUD naloxone Vanderbilt Source Type: research
Healthcare provider perspectives on emergency department-initiated buprenorphine/naloxone: a qualitative study
Take-home buprenorphine/naloxone is an effective method of initiating opioid agonist therapy in the Emergency Department (ED) that requires ED healthcare worker buy-in for large-scale implementation. We aimed ... (Source: BMC Health Services Research)
Source: BMC Health Services Research - February 15, 2024 Category: General Medicine Authors: Katherin Badke, Serena S. Small, Megan Pratt, Julie Lockington, Lara Gurney, Andrew Kestler and Jessica Moe Tags: Research Source Type: research
Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians
by Nathalie MacKinnon, Daniel Lane, Frank Scheuermeyer, Janusz Kaczorowski, Kathryn Dong, Aaron M. Orkin, Raoul Daoust, Jessica Moe, Gary Andolfatto, Michelle Klaiman, Justin Yan, Justin J. Koh, Kathryn Crowder, Paul Atkinson, David Savage, James Stempien, Floyd Besserer, Jason Wale, Andrew Kestler
ObjectiveTo identify individual and site-related factors associated with frequent emergency department (ED) buprenorphine/naloxone (BUP) initiation. BUP initiation, an effective opioid use disorder (OUD) intervention, varies widely across Canadian EDs. MethodsWe surveyed emergency physicians in 6 Canadian provinces from 2018 to ...
Source: PLoS One - February 5, 2024 Category: Biomedical Science Authors: Nathalie MacKinnon Source Type: research
Guanfacine Treatment in a Patient with Intravenous Buprenorphine/Naloxone Misuse
Case Rep Psychiatry. 2024 Jan 19;2024:6359691. doi: 10.1155/2024/6359691. eCollection 2024.ABSTRACTIn this case report, we described a patient admitted with buprenorphine/naloxone (BN) misuse, accompanied by intermittent pregabalin misuse, to self-treat the opioid withdrawal symptoms. We treated the withdrawal symptoms after cessation of BN with guanfacine extended-release (XR). To our knowledge, it has been the first case report describing guanfacine-XR in the treatment of BN misuse. Notably, our patient responded to the treatment with a decrease in withdrawal symptoms without any significant side-effect. Although it is n...
Source: Case Reports in Psychiatry - January 29, 2024 Category: Psychiatry Authors: Sercan Karabulut Source Type: research
Outpatient cross-titration to buprenorphine for chronic pain: A retrospective analysis
DISCUSSION: The University of Washington's buprenorphine cross-titration protocol for chronic pain was successful in about half of included patients undergoing conversion from chronic full µ-opioid agonist therapy and generally well tolerated. Clinical responses were widely variable, and many required slower taper and higher end-titration buprenorphine dose than anticipated. Although protocols provide structure for cross-titration, each course should be monitored closely and individualized.PMID:38189196 | DOI:10.5055/jom.0839 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - January 8, 2024 Category: Addiction Authors: Satoru Ito Mackenzie Welsh Christina Bockman Rebecca Dale David Pilkington Katherin Peperzak Source Type: research
